This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-12. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
== Pharmacokinetics == After oral ingestion, glycyrrhizin is hydrolysed to 18β-glycyrrhetinic acid (enoxolone) by intestinal bacteria. After absorption from the gut, 18β-glycyrrhetinic acid is metabolised to 3β-monoglucuronyl-18β-glycyrrhetinic acid in the liver. This metabolite circulates in the bloodstream. Consequently, its oral bioavailability is poor. Most of it is eliminated by bile and only a minor part (0.31–0.67%) by urine. After oral ingestion of 600 mg of glycyrrhizin the metabolite appeared in urine after 1.5 to 14 hours. Maximal concentrations (0.49 to 2.69 mg/L) were achieved after 1.5 to 39 hours and metabolite can be detected in the urine after 2 to 4 days.
In 2007 a 10-year-old male Dalmatian dog was described with acromegalic signs such as an enlarged tongue and head, widened interdental space, and thickening of skin; along with other signs of hypersomatotropism such as polyphagia, obesity, and stridor. Insulin levels were heightened and the dog had glucose intolerance; however, the dog was not diabetic as blood glucose levels were found to be normal after multiple tests. Levels of IGF-1 and growth hormone were heightened. CT imaging showed a pituitary mass which was later confirmed to be an acidophilic adenoma stained for growth hormone; however, mammary tumour-induced acromegaly is rare with few reported cases. Hypothyroidism can increase levels of growth hormone and IGF-1 in dogs. Some of the physical changes in dogs with hypothyroidism may be due to increased growth hormone concentration.
Loss of perivascular collagen occurs; it is thought that this is due to the degradative enzymes released by extravasating leukocytes, such that the collagen and other connective tissue fibers surrounding blood vessels in the area dissolve. When this occurs the gums will appear bright red and either bulbous or rounded, from all the excess fluid building up in the infected area. The initial lesion appears within two to four days of gingival tissue being subjected to plaque accumulation. When not generated through clinical experimentation, the initial lesion may not appear at all, and instead, a detectable infiltrate similar to that of the early lesion, explained below, appears.
It was first synthesised in 1811 by Pierre Louis Dulong, who lost three fingers and an eye to its explosive tendencies. As a dilute gas it is less dangerous and is thus used industrially to bleach and sterilise flour. Nitrogen tribromide (NBr3), first prepared in 1975, is a deep red, temperature-sensitive, volatile solid that is explosive even at −100 °C. Nitrogen triiodide (NI3) is still more unstable and was only prepared in 1990. Its adduct with ammonia, which was known earlier, is very shock-sensitive: it can be set off by the touch of a feather, shifting air currents, or even alpha particles. For this reason, small amounts of nitrogen triiodide are sometimes synthesised as a demonstration to high school chemistry students or as an act of "chemical magic". Chlorine azide (ClN3) and bromine azide (BrN3) are extremely sensitive and explosive. Two series of nitrogen oxohalides are known: the nitrosyl halides (XNO) and the nitryl halides (XNO2). The first is very reactive gases that can be made by directly halogenating nitrous oxide. Nitrosyl fluoride (NOF) is colourless and a vigorous fluorinating agent. Nitrosyl chloride (NOCl) behaves in much the same way and has often been used as an ionising solvent. Nitrosyl bromide (NOBr) is red. The reactions of the nitryl halides are mostly similar: nitryl fluoride (FNO2) and nitryl chloride (ClNO2) are likewise reactive gases and vigorous halogenating agents.
After the war, the Grand Lodge of Cuba was reopened in Havana and was allowed to continue its normal function. It was the only institution of Cuban civil society from before the Revolution that the Castros, Che, and the new Marxist government did not completely dismantle. Some historians argue that Castro only wanted to use it as an extension of the Communist Party of Cuba and a method to control the population, while others argue that he felt a unique bond with Freemasonry where no other institution had impacted the revolutionary history of Cuba so much. In 1960, after the leadership of the Grand Lodge fled the country, Deputy Grand Master Aurelio Alvarez took over the office as Acting Grand Master for a short time, but Aurelio Alvarez also fled the country not long after. Former Senior Grand Warden Manuel Céspedes Mora took over as Grand Master. Between 1960 and 1965, there was no stability in the leadership of the Grand Lodge, as Grand Masters routinely resigned, fled the country, or were arrested. At regular meetings of the Grand Lodge of Cuba, there were debates about the possibility of openly criticizing the new government, or if whether to survive, they needed to put their support behind Castro. Grand Master Jorge Luis Cuervo Calvo was arrested by the Cuban government alongside several other members of the Grand Lodge of Cuba for conspiracy against the government, and some Grand Lodge officers actively supported this coup attempt.
Sources: en.wikipedia.org
== World Accreditation Day (WAD) == NABL celebrates World Accreditation Day (WAD) every year on 9 June. World accreditation day is celebrated to provide awareness on accreditation and how accreditation benefits its stakeholders.
== Prevention == Opioid overdoses can often be prevented. Clear protocols for staff at emergency departments and urgent care centers can reduce opioid prescriptions for individuals presenting in these settings who engage in drug seeking behaviors or who have a history of a substance use disorder. Drug seeking behaviors include but are not limited to obsessiveness or impatience when it comes to attaining medications, seeking multiple pain adjunct medications, and inconsistent physiological presentation. A prescription monitoring program may help determine if an individual is receiving a high doses of opioids or combinations of medications such as benzodiazepines and opioids that put them at high risk. Limited amount of evidence suggests opioid therapy with extended-release or long-acting formulations may increase the risk of an unintentional overdose compared to shorter-acting agents. Routinely screening using tools such as the CAGE-AID and the Drug Abuse Screening Test (DAST-10) in adults and the CRAFFT in those aged 14–18 years is recommended. The revised risk index for overdose or severe opioid induced respiratory depression (RIOSORD) is a validated screening tool that may be used to estimate the risk of overdose in people using opioids, or the rapid opioid dependence screen may be used as a more rapid and succinct method to screen for opioid use disorder. Other "drug seeking" behaviors and physical indications of drug use should be used as clues to perform formal screenings.
=== Pharmacokinetics === After ingestion, bisoprolol is absorbed and has a high bioavailability of approximately 90% with a plasma half-life of 10–12 hours. Typically, half the circulating bisoprolol is metabolized by the liver, the rest passing unchanged through the kidneys before elimination; less than 2% may be excreted in the feces. Bisoprolol is soluble in both lipids and water. It is classified as a beta blocker with moderate lipophilicity and hence intermediate potential for crossing the blood–brain barrier. This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects than highly lipophilic beta blockers like propranolol but greater such effects than beta blockers with low lipophilicity like atenolol. The plasma protein binding of bisoprolol is approximately 35%, the volume of distribution is 3.5 L/kg and the total clearance is approximately 15 L/h. Bisoprolol is eliminated from the body in two ways - 50% of the substance is converted in the liver to inactive metabolites, which are then excreted in the kidneys. The remaining 50% is eliminated unchanged via the kidneys. Since elimination is equal in liver and kidney, no dose adjustment is required in patients with hepatic or renal impairment. The pharmacokinetics of bisoprolol are linear and independent of age. In patients with chronic heart failure, the plasma level of bisoprolol is higher and the half-life is longer than in healthy subjects when compared across studies.
14 March – SpaceX successfully launches the Starship spacecraft, but loses the rocket upon re-entering the atmosphere. 19 March Scientists demonstrate a wireless network of 78 tiny sensors able to gather data from the brain, with potential to be scaled up to thousands of such devices. Researchers with the National Severe Storms Laboratory, Storm Prediction Center, CIWRO, and the University of Oklahoma's School of Meteorology publish a paper where they state, ">20% of supercell tornadoes may be capable of producing EF4–EF5 damage" and that "the legacy F-scale wind speed ranges may ultimately provide a better estimate of peak tornado wind speeds at 10–15 m AGL for strong–violent tornadoes and a better damage-based intensity rating for all tornadoes" and also put the general 0–5 ranking scale in question. 20 March – The removal of HIV from infected cells using CRISPR gene editing technology is reported. 26 March – A study outlines identified ecological pandemic prevention measures for policy frameworks.
Sources: en.wikipedia.org
=== Other liquids === For example, hydrogen fluoride—which has three lone pairs on the F atom but only one H atom—can form only two bonds. Ammonia has the opposite problem: three hydrogen atoms but only one lone pair.
== Advantages == The advantages of this method include good separation of large molecules from the small molecules with a minimal volume of eluate, and that various solutions can be applied without interfering with the filtration process, all while preserving the biological activity of the particles to separate. The technique is generally combined with others that further separate molecules by other characteristics, such as acidity, basicity, charge, and affinity for certain compounds. With size exclusion chromatography, there are short and well-defined separation times and narrow bands, which lead to good sensitivity. There is also no sample loss because solutes do not interact with the stationary phase. The other advantage to this experimental method is that in certain cases, it is feasible to determine the approximate molecular weight of a compound. The shape and size of the compound (eluent) determine how the compound interacts with the gel (stationary phase). To determine approximate molecular weight, the elution volumes of compounds with their corresponding molecular weights are obtained and then a plot of "Kav" vs "log(Mw)" is made, where
Probable migraine describes conditions that have some characteristics of migraine, but where there is not enough evidence to diagnose it as migraine with certainty. Menstrual migraines are those that either only occur associated with a menstrual period, or occur predictably around menstrual period alongside migraines during other parts of the menstrual cycle. They typically occur in migraines without aura. They are often longer than other migraine attacks, and associated with more nausea.
== Similar approaches == Though immunoliposomes serve as a possible advancement, there are other therapies similar to it that trail on the role of targeted drug delivery systems. One example of such therapy is Immune Polymeric nanoparticles, which are similar to liposomes but consist of small particles composed of biodegradable polymers. These nanoparticles similarly encapsulate drugs and can function to enhance specificity towards targeted diseased cells with peptide ligands. Another type is Targeting Antibody Drug Conjugates, which combine monoclonal antibodies with the cytotoxicity of chemotherapy drugs. This specific type is catered towards cancer cells expressing a specific target antigen. They are well-tolerated by the body as they are biodegradable, eliminating many potential toxicity factors, and proving to be a possible new model for therapeutics.
== Detection by mass spectrometry == A mass spectrum of an organic compound will usually contain a small peak of one mass unit greater than the apparent molecular ion peak (M) of the whole molecule. This is known as the M+1 peak and comes from the few molecules that contain a 13C atom in place of a 12C. A molecule containing one carbon atom will be expected to have an M+1 peak of approximately 1.1% of the size of the M peak, as 1.1% of the molecules will have a 13C rather than a 12C. Similarly, a molecule containing two carbon atoms will be expected to have an M+1 peak of approximately 2.2% of the size of the M peak, as there is double the previous likelihood that any molecule will contain a 13C atom. In the above, the mathematics and chemistry have been simplified. However it can be used effectively to give the number of carbon atoms for small- to medium-sized organic molecules. In the following formula, the result should be rounded to the nearest integer:
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.